Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EYP-1901 (vorolanib) (EyePoint Pharmaceuticals)
- Development stage
- Unknown
- Lead developer
- EyePoint Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Intravitreal
01
Overview
EYP-1901 (DURAVYU) is a bioerodible intravitreal insert developed by EyePoint Pharmaceuticals for the treatment of serious retinal diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and non-proliferative diabetic retinopathy (NPDR). The product utilizes the proprietary Durasert E technology to provide sustained release of vorolanib, a small molecule tyrosine kinase inhibitor (TKI), for approximately six to nine months following a single injection. Vorolanib features a multi-mechanism of action, working intracellularly to suppress angiogenesis by inhibiting all isoforms of vascular endothelial growth factor receptors (VEGFR) and platelet-derived growth factor receptors (PDGFR), while also suppressing inflammation via the inhibition of interleukin-6 (IL-6) signaling. EYP-1901 is designed to reduce the treatment burden associated with frequent anti-VEGF injections by maintaining therapeutic drug levels over an extended period.
- Brand names
- DURAVYU
- Other names
- vorolanib intravitreal insert
02
Targets
IL-6 (Interleukin 6)JAK1 (Janus kinase 1)JAK2 (Janus kinase 2)JAK3 (Janus kinase 3)PDGFRB (Platelet-derived growth factor receptor beta)TEK (Tie2)TYK2 (Tyrosine kinase 2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on EYP-1901 (vorolanib) (EyePoint Pharmaceuticals).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EYP-1901 (vorolanib) (EyePoint Pharmaceuticals).